identification and lead optimization of a series of pyridopyrimidinone derivatives are described as a novel class of efficacious dual PI3K/mTOR inhibitors, resulting in the discovery of 31. Compound 31 exhibited high enzyme activity against PI3K and mTOR, potent suppression of Akt and p70s6k phosphorylation in cell assays, and good pharmacokinetic profile. Furthermore, compound 31 demonstrated in vivo
一系列
嘧啶嘧啶酮衍
生物的鉴定和前导优化被描述为一类新型的有效
PI3K / mTOR双重
抑制剂,导致31的发现。化合物31在
细胞分析中显示出对
PI3K和mTOR的高酶活性,对Akt和p70s6k
磷酸化的有效抑制作用,以及良好的药代动力学特征。此外,化合物31在PC-3M肿瘤异种移植模型中显示出体内功效。